# US 2013/0158096 A1 · Mirnas involved in the blood brain barrier function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158096 A1
- Document ID: US20130158096A1
- Status: Published application
- Kind: A1
- Application number: 13/700,624
- Filed: 2011-05-27
- Published: 2013-06-20
- Earliest claimed: 2002-01-22
- Assignees: Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
- Inventors: Arie Reijerkerk; Helga Eveline De Vries
- Web page: https://patentgrep.com/patent/US20130158096A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/351: Conjugate
- C12N 2320/10: in screening processes
- C12N 2330/10: naturally occurring
- C12Q 2600/136: Screening for pharmacological compounds
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The current invention relates to use of particular nucleic acids for modulating (increasing or decreasing) blood-brain barrier function, and for use of such nucleic acids in treatment of conditions involving blood brain barrier function, including multiple sclerosis, HIV infection, Alzheimer's disease, Parkinson's disease, epilepsy, and so on. Also provided is an assay for identifying drugs useful in modulating blood brain barrier function.

## Claims

### Claim 1

A method for increasing blood-brain barrier function, comprising introducing to or expressing in brain endothelial cells a nucleic acid comprising a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 100% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152.

### Claim 2

A nucleic acid comprising a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 99% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152, wherein said nucleic acid is not a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152.

### Claim 3 (depends on 2)

The nucleic acid according to claim 2, wherein the nucleic acid comprises a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 99% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-120, preferably SEQ ID No 1-100, more preferably SEQ ID No 1-80, and most preferably SEQ ID No 32, 37, 38, 53, and 80.

### Claim 4 (depends on 2)

The nucleic acid according to claim 2, wherein the nucleic acid is a pre-miRNA, pri-miRNA, a siRNA or a shRNA.

### Claim 5 (depends on 2)

A method of treatment for increasing blood-brain barrier function, comprising introducing to or expressing in brain endothelial cells the nucleic acid according to claim 2.

### Claim 6 (depends on 5)

The method of claim 5, wherein the treatment is for stroke, brain trauma, infection, inflammation, multiple sclerosis, HIV infection, Alzheimer's disease, Parkinson's disease, epilepsy, brain tumours, glaucoma and lysosomal storage diseases, prion disease, retinal dysfunction, cerebrovascular disease, migraine, or peroxisome-associated diseases.

### Claim 7

A method for decreasing blood-brain barrier function, comprising blocking a nucleic acid which comprises the nucleic acid sequence selected from the group of SEQ ID NO:1-152 with a blocking nucleic acid comprising a nucleic acid sequence of which at least 8 adjacent nucleotides are at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 100% complementary to 8 adjacent nucleotides of a nucleic acid sequence selected from the group of SEQ ID No 1-152.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the blocking nucleic acid comprises a nucleic acid sequence of which at least 8 adjacent nucleotides are at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 99% complementary to 8 adjacent nucleotides of nucleic acid sequence selected from the group consisting of SEQ ID No 1-120, preferably SEQ ID No 1-100, more preferably SEQ ID No 1-80, and most preferably SEQ ID No 32, 37, 38, 53 and 80.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the blocking nucleic acid comprises a nucleotide analogue.

### Claim 10

(canceled)

### Claim 11 (depends on 7)

The method according to claim 7, which is a treatment for infection, inflammation, multiple sclerosis, HIV infection, Alzheimer's disease, Parkinson's disease, epilepsy, brain tumours, glaucoma, lysosomal storage diseases, prion disease, retinal dysfunction, cerebrovascular disease, migraine, or peroxisome-associated diseases.

### Claim 12 (depends on 2)

The nucleic acid according to claim 2, wherein the nucleic acid is coupled to a ligand for delivery in endothelial brain cells.

### Claim 13 (depends on 2)

A delivery vehicle comprising the nucleic acid according to claim 2.

### Claim 14 (depends on 2)

A method for modulating blood brain barrier function, comprising introducing the nucleic acid according to claim 2 to brain endothelial cells.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the nucleic acid introduced in vivo.

### Claim 16 (depends on 25)

The method according to claim 25, wherein the nucleic acid delivery vehicle is introduced in a cell, preferably a brain endothelial cell.

### Claim 17 (depends on 16)

The method according to claim 16, wherein preferably the brain endothelial cell is a primary cell or a cell line, preferably derived from vertebrate species, preferably man, most preferably the brain endothelial cell line is HCMEC/D3.

### Claim 18

An assay for screening for compounds that modulate the blood brain barrier function comprising the steps of:
incubating a cell in the presence of a compound to be tested,
determining the expression level of a nucleic acid sequence selected from the group of SEQ ID No 1-152,
wherein the expression level of said nucleic acid sequence is compared with the expression level of said nucleic acid sequence as determined in a cell incubated without the presence of said compound to be tested.

### Claim 19 (depends on 18)

The assay according to claim 18, wherein determining the expression level is of a nucleic acid sequence selected from the group consisting of SEQ ID No 1-120, preferably SEQ ID No 1-100, more preferably SEQ ID No 1-80, and most preferably SEQ ID No 32, 37, 38, 53 and 80.

### Claim 20 (depends on 18)

The assay according to claim 18, wherein in the step of incubating a cell in the presence of a compound to be tested, astrocyte conditioned medium is present as well and/or wherein the assay further comprises the step of:
incubating the cell in the presence of astrocyte conditioned medium, before and/or or after the step of incubating a cell in the presence of a compound to be tested.

### Claim 21 (depends on 18)

The assay according to claim 18, wherein the cell is a brain endothelial cell, preferably a brain endothelial cell line, preferably the brain endothelial cell line is HCMEC/D3.

### Claim 22 (depends on 18)

The assay according to claim 18, wherein the expression level is determined with a microarray a PCR reaction, a quantitative PCR or a reporter gene construct.

### Claim 23 (depends on 1)

The method according to claim 1, wherein the nucleic acid comprises a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 99% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-120, preferably SEQ ID No 1-100, more preferably SEQ ID No 1-80, and most preferably SEQ ID No 32, 37, 38, 53, and 80.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the nucleic acid is a pre-miRNA, pri-miRNA, a siRNA or a shRNA.

### Claim 25 (depends on 13)

A method for modulating blood brain barrier function, comprising introducing the delivery vehicle according to claim 13 to brain endothelial cells.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the delivery vehicle is introduced in vivo.
